Support Alert

Drug safety update: Naltrexone/bupropion (Mysimba)

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update that patients should be advised that naltrexone/bupropion has been associated with adverse reactions such as dizziness or somnolence, which can affect ability to drive, operate machinery, or perform dangerous tasks. Advise patients not to drive if they suspect their ability may be impaired. 

Loading...
Photo of a happy pharmacist saving money on her RPS membership

Join today with an Annual Direct Debit

Become an RPS Member today and save up to £26 by choosing annual Direct Debit
OR spread the cost by switching to monthly payments.

RPS membership is better value than ever in 2024 - join today!

BECOME A MEMBER TODAY